These results indicate that the motility-suppressing effects of miR-33b-3p on prostate cancer cells were associated with downregulation of DOCK4. Analysis of DOCK4 expression in prostate cancer patients using TCGA and UALCAN datasets (http://ualcan.path.uab.edu/index.html) showed that the level of DOCK4 had no difference between different T or N stages (Supplementary Figures 4A, B). This evidence concerns the gene DOCK4 and prostate carcinoma.